Affiliation:
1. Indiana Alzheimer’s Disease Research Center, Indianapolis, IN 46202, USA
2. Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN 46202, USA
3. Department of Radiology and Imaging Sciences, Indiana University School of Medicine, Indianapolis, IN 46202, USA
4. School of Informatics and Computing, Indiana University, Indianapolis, IN 46202, USA
5. Department of Biostatistics, Indiana University School of Medicine, Indianapolis, IN 46202, USA
6. Department of Biostatistics, Epidemiology and Informatics, The Perelman School of Medicine, Philadelphia, PA 19104, USA
Abstract
The underlying genetic susceptibility for Alzheimer’s disease (AD) is not yet fully understood. The heterogeneous nature of the disease challenges genetic association studies. Endophenotype approaches can help to address this challenge by more direct interrogation of biological traits related to the disease. AD endophenotypes based on amyloid-β, tau, and neurodegeneration (A/T/N) biomarkers and cognitive performance were selected from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) cohort (N = 1565). A genome-wide association study (GWAS) of quantitative phenotypes was performed using an SNP main effect and an SNP by Diagnosis interaction (SNP × DX) model to identify disease stage-specific genetic effects. Nine loci were identified as study-wide significant with one or more A/T/N endophenotypes in the main effect model, as well as additional findings significantly associated with cognitive measures. These nine loci include SNPs in or near the genes APOE, SRSF10, HLA-DQB1, XKR3, and KIAA1671. The SNP × DX model identified three study-wide significant genetic loci (BACH2, EP300, and PACRG-AS1) with a neuroprotective effect in later AD stage endophenotypes. An endophenotype approach identified novel genetic associations and provided insight into the molecular mechanisms underlying the genetic associations that may otherwise be missed using conventional case-control study designs.
Funder
National Institutes of Health
Department of Defense
National Library of Medicine
National Institute of Aging
National Institute of General Medicine Sciences
National Center for Advancing Translational Sciences
Alzheimer’s Association
Indiana Clinical and Translational Science Institute
IU Health-IU School of Medicine Strategic Neuroscience Research Initiative
National Institute of Biomedical Imaging and Bioengineering
AbbVie
Alzheimer’s Drug Discovery Foundation
Araclon Biotech
BioClinica, Inc.
Biogen
Bristol-Myers Squibb Company
CereSpir, Inc.
Cogstate
Eisai Inc.
Elan Pharmaceuticals, Inc.
Eli Lilly and Company
EuroImmun
F. Hoffmann-La Roche Ltd.
Genentech, Inc.
Fujirebio
GE Healthcare
IXICO Ltd.
Janssen Alzheimer Immunotherapy Research & Development, LLC.
Johnson & Johnson Pharmaceutical Research & Development LLC.
Lumosity
Lundbeck
Merck & Co., Inc.
Meso Scale Diagnostics, LLC.
NeuroRx Research
Neurotrack Technologies
Novartis Pharmaceuticals Corporation
Pfizer Inc.
Piramal Imaging
Servier
Takeda Pharmaceutical Company
Transition Therapeutics
Canadian Institutes of Health Research
Foundation for the National Institutes of Health
Northern California Institute for Research and Education
University of Southern California
Alzheimer’s Disease Genetics Consortium
Lilly Endowment, Inc.
Indiana University Pervasive Technology Institute
Subject
Genetics (clinical),Genetics